A clinical trial to study the effects of two drugs, viladozone and fluoxetine in major depressive patients for 6 weeks

A 6 week prospective open label comparative study of efficacy and safety of vilazodone and fluoxetine in major depressive disorder

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/03/008202

Enrollment

Registered

2017-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- MAJOR DEPRESSIVE DISORDER

Interventions

Intervention1: Tab vilazodone 20-40mg: Tab vilazodone 20-40mg orally,daily morning after food for 6 weeks Control Intervention1: Cap fluoxetine 20-60mg: Cap fluoxetine 20-60mg,orally once daily mornin

Eligibility

Inclusion criteria

Inclusion criteria: •subjects diagnosed with major depressive disorder, first episode (according to DSM -V criteria) or recurrent episodes. •Age: 18-65 years. •Both sexes. •Subjects who give informed consent.

Exclusion criteria

Exclusion criteria: •Severe depressive episode with suicidal/poor insight subject who is unable to give informed consent. •Subjects with any serious concurrent medical and psychiatric illness. •Presence of organic brain syndromes including delirium and dementia.

Design outcomes

Primary

Measure	Time frame
EfficacyTimepoint: Baseline(before medication), 3rd week, 6th week	—

Secondary

Measure	Time frame
Side effect profileTimepoint: 3rd week and 6th week	—

Countries

India

Contacts

Public ContactDr Usharani H Patted

Mysore medical college and research institute

dr.hema_ng@yahoo.com9449621172

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026